Melastatin-related transient receptor potential channel 2 (TRPM2) is a Ca 2؉ -permeable, nonselective cation channel that is involved in oxidative stress-induced cell death and inflammation processes. Although TRPM2 can be activated by ADP-ribose (ADPR) in vitro, it was unknown how TRPM2 is gated in vivo. Moreover, several alternative spliced isoforms of TRPM2 identified recently are insensitive to ADPR, and their gating mechanisms remain unclear. Here, we report that intracellular Ca 2؉ ( Ca 2ϩ signaling ͉ gating mechanism ͉ ADP-ribose ͉ calmodulin-binding domain ͉ oxidative stress T ransient receptor potential (TRP) channels have been shown to play important roles under physiological and pathological conditions (1-3). TRPM2, also referred to as TRPC7 (4) or LTRPC2 (5-7), is a member of the melastatin-related (TRPM) TRP channel subfamily, which possesses both ion-channel and ADP-ribose (ADPR) hydrolase functions (5-7). TRPM2 is a Ca 2ϩ -permeable, nonselective cation channel that is predominantly expressed in various regions of the brain and is also expressed in other tissues, including spleen, heart, liver, lung, and bone marrow (4-6). Studies at cellular levels have implicated that TRPM2 is involved in oxidative stress-mediated cortical and striatal neuronal cell death (8, 9), hematopoietic cell death (5, 8, 10), and insulin secretion (11). A recent report demonstrated that TRPM2 regulates reactive oxygen species-induced chemokine production in monocytes, thereby aggravating inflammation (12).
T ransient receptor potential (TRP) channels have been shown to play important roles under physiological and pathological conditions (1) (2) (3) . TRPM2, also referred to as TRPC7 (4) or LTRPC2 (5) (6) (7) , is a member of the melastatin-related (TRPM) TRP channel subfamily, which possesses both ion-channel and ADP-ribose (ADPR) hydrolase functions (5) (6) (7) . TRPM2 is a Ca 2ϩ -permeable, nonselective cation channel that is predominantly expressed in various regions of the brain and is also expressed in other tissues, including spleen, heart, liver, lung, and bone marrow (4) (5) (6) . Studies at cellular levels have implicated that TRPM2 is involved in oxidative stress-mediated cortical and striatal neuronal cell death (8, 9) , hematopoietic cell death (5, 8, 10) , and insulin secretion (11) . A recent report demonstrated that TRPM2 regulates reactive oxygen species-induced chemokine production in monocytes, thereby aggravating inflammation (12) .
TRPM2 has been shown to be activated by ADPR (6, 7), oxidative stress (5, 13, 14) , NAD ϩ (5, 7, 15) , cADPR, and nicotinic acid adenine dinucleotide phosphate (NAADP) (16, 17) . ADPR activates TRPM2 by directly binding to the channel's enzymatic NUDT9-H domain (18, 19) . Different mechanisms have been proposed for H 2 O 2 -mediated TRPM2 gating. Some studies suggest that H 2 O 2 activates TRPM2 via intracellular release of ADPR (19) or by converting NADH to NAD ϩ (5), whereas other studies support a direct activation mechanism (20) , as evidenced by H 2 O 2 -mediated activation of whole-cell TRPM2 currents (13) and singlechannel currents (14) . Further, NAADP and cADPR have been reported to activate TRPM2 either directly or in synergy with ADPR in Jurkat T cells and heterologously expressed HEK-293 cells (16, 17) . However, another study demonstrated that cADPR was incapable of TRPM2 activation in neutrophil granulocytes (21) . These discrepancies about mechanisms of TRPM2 activation may be attributable to differences in expression systems or cell lines. Moreover, different intracellular Ca 2ϩ concentrations used in different studies also may have contributed to the controversial results.
Intracellular Ca 2ϩ ([Ca 2ϩ ] i ) is involved in a variety of cellular functions. It has been suggested that [Ca 2ϩ ] i is a modulator for ADPR-and cADPR-mediated TRPM2 activation (6, 22) . An increase in [Ca 2ϩ ] i level significantly reduces the ADPR concentration required for TRPM2 activation (6) . External Ca 2ϩ also has been shown to influence ADPR-mediated TRPM2 gating (22, 23) . However, the detailed mechanisms by which Ca 2ϩ synergizes with ADPR in activating TRPM2 remain unknown.
Whereas the gating mechanism and physiological functions of the full-length TRPM2 have been studied extensively, information pertaining to TRPM2 alternative spliced isoforms is largely unavailable (24) . Several splice variants of TRPM2 have been identified, including a shorter form (SSF-TRPM2) in which the Nterminal 214-aa residues are removed (25), a C-terminal truncation (TRPM2-⌬C) lacking exon 27, and an N-terminal truncation (TRPM2-⌬N) lacking a portion of exon 11 (13, 15) . Although the full-length TRPM2 can be activated by ADPR, NAD ϩ , and H 2 O 2 , it appears that the spliced isoforms cannot be activated by the known activators for the full-length TRPM2 (18, 24, 26) . Therefore, it was unclear whether the spliced isoforms can form functional channels (18, 24, 26) . Insufficient knowledge about the gating mechanism of the alternative spliced isoforms of TRPM2 largely hampered the investigation of their physiological and/or pathological functions.
A better understanding of TRPM2 gating mechanism as well as how TRPM2 alternative spliced isoforms can be activated is essential for uncovering physiological functions of TRPM2 and its spliced isoforms. Here, we report that [Ca 2ϩ ] i alone can activate both full-length TRPM2 and its spliced isoforms. Importantly, Ca 2ϩ release from intracellular Ca 2ϩ stores is able to activate TRPM2 in intact cells. Given that endogenous ADPR, cADPR, NAD ϩ , and NAADP concentrations are much lower than those required for TRPM2 activation (16), [Ca 2ϩ ] i -mediated gating of TRPM2 and its spliced isoforms may represent one of the major gating mechanisms in vivo, and therefore may confer a variety of physiological and pathological functions of TRPM2 and its spliced isoforms. shown in Fig. 1 A and (27) , [Ca 2ϩ ] i -activated TRPM2 was completely and reversibly blocked by 20 M ACA ( Fig. 1 A and B) . Moreover, [Ca 2ϩ ] i activated TRPM2 in a concentration-dependent manner, with an EC 50 of 16.9 M (Fig. 1G) . The EC 50 was decreased to 0.49 M by 10 M ADPR, suggesting a synergistic effect of ADPR and Ca 2ϩ . The current amplitude of TRPM2 was about 2.5-fold greater when 10 M ADPR was included in the pipette solution (Fig. 1G Inset) . And the time required for TRPM2 activation was significantly shortened by ADPR (Fig. S1 ). These results indicate that [Ca 2ϩ ] i is sufficient for TRPM2 activation, and the effect of Ca 2ϩ can be synergized by ADPR. In agreement with this notion, application of Ca 2ϩ alone in the cytosolic side was able to activate single-channel openings of TRPM2 in inside-out patches (Fig. 1C) . The singlechannel currents of TRPM2 elicited by Ca 2ϩ (Fig. 1C) were similar to those activated by ADPR/Ca 2ϩ (Fig. 1F) ADPR activates TRPM2 via binding to the ADPR-binding cleft at the C terminus of TRPM2 (19, 28) . Mutations of TRPM2, N1326D, and I1405E/L1406F result in nonfunctional channels that cannot be activated by ADPR, NAD, or other known activators (18) . Because we have shown that [Ca 2ϩ ] i -mediated TRPM2 activation is independent of ADPR (Fig. 1) , we then investigated whether the ADPR-insensitive mutants can be activated by [Ca 2ϩ ] i . Although the ADPR-containing pipette solution (100 nM Ca 2ϩ /200 M ADPR) used for activating WT TRPM2 failed to activate N1326D and I1405E/L1406F mutants (Fig. S2C) , [Ca 2ϩ ] i alone (100 M) activated both N1326D (Fig. 2 A and C) and I1405E/L1406F mutants ( Fig. S2 A and B) . Immunostaining demonstrated that TRPM2 proteins were expressed in WT TRPM2-transfected and N1326D-transfected cells but not in mock-transfected cells (Fig.  2B) . ADPR (200 M) failed to influence the current amplitude of N1326D activated by [Ca 2ϩ ] i , although it significantly increased WT TRPM2 current amplitude (Fig. 2D) , indicating that N1326D is indeed a mutant insensitive to ADPR. Similar results were obtained for the I1405E/L1406F mutant (Fig. S2) . Like WT TRPM2, N1326D was activated by [Ca 2ϩ ] i in a concentration-dependent manner (Fig. 2C) . Moreover, Ca 2ϩ was able to elicit single-channel opening of N1326D in inside-out patches. Single-channel properties and conductance ( Fig. 2 E and F ) of N1326D were similar to those of WT TRPM2 ( Fig. 1 F and H) pA/pF, n ϭ 10; TRPM2 and CaM, 244.5 Ϯ 51.0 pA/pF, n ϭ 7; P Ͼ 0.05), presumably because of sufficient expression of endogenous CaM. However, when the CaM mutant CaM1-4, with mutations at 4 EF hands (CaM1-4) was cotransfected with either WT TRPM2 or N1326D (Fig. 3B) , their current amplitude decreased significantly, suggesting a potential role for CaM in [Ca 2ϩ ] i -mediated TRPM2 activation. We then created a TRPM2 mutant (Fig. 3A) via substitution of the IQ-like motif, based on a previous study suggesting that an IQ-like motif in the N terminus of TRPM2 binds to CaM and is involved in H 2 O 2 -induced Ca 2ϩ influx through TRPM2 (29) . Although the IQ-mut was able to express TRPM2 protein as detected by immunostaining (Fig. S3) , IQ-mut could not be activated by [Ca 2ϩ ] i at 100 M (Fig. 3D) . Examination of surface protein of IQ-mut yielded similar expression levels in comparison with WT TRPM2 and N1326D (Fig. 3C) . And the ratio of membrane versus cytosol protein was also similar among WT TRPM2, IQ-mut, and N1326D. Thus, the nonfunctional IQ-mut indicates that the CaM-binding site is essential for [Ca 2ϩ ] i activation of TRPM2 (Fig. 3E) . Moreover, the IQ-mut could not be activated by addition of ADRP (200 M) in the pipette solution (Fig. 3E) ] i was capable of TRPM2 spliced isoform activation. We created the following truncation mutants to mimic the endogenous spliced isoforms: TRPM2-⌬N, TRPM2-⌬C, and TRPM2-⌬N/⌬C (Fig. 4A) . Although 100 nM Ca 2ϩ /1 mM ADPR failed to elicit any current (Fig.  4E) , intracellular Ca 2ϩ alone at 10 M remarkably activated TRPM2-⌬N, TRPM2-⌬C, and TRPM2-⌬N/⌬C (Fig. 4 B and C) . Concentration-dependent activation of TRPM2-⌬N, TRPM2-⌬C, and TRPM2-⌬N/⌬C by [Ca 2ϩ ] i also was observed (Fig. 4D) Fig. 5A , under the perforated patch configuration, no currents were elicited by the voltage-ramp protocol before application of ionomycin. However, extracellular perfusion of 5 M ionomycin evoked substantial TRPM2 channel activation (Fig. 5A) . After cell rupture, current amplitude was dramatically increased because of the dialysis of ADPR from pipette solution into cytosol ( Fig. 5 A and B) . To verify that it was the change of [Ca 2ϩ ] i that activated TRPM2, we did simultaneous current recording and Ca 2ϩ concentration measurement. As illustrated in Fig. 5C , an increase in [Ca 2ϩ ] i led to TRPM2 activation, which in turn increased intracellular Ca 2ϩ levels.
Because ionomycin may mobilize both intracellular and extracellular Ca 2ϩ , we further investigated whether Ca 2ϩ release could activate TRPM2 in perforated whole-cell current recordings. Fig. 5 E and F show that 100 M tert-butylhydroquinone (TBHQ), a Ca 2ϩ pump blocker, induced intracellular Ca 2ϩ release that was sufficient to activate TRPM2. The mean current amplitude of TRPM2 elicited by TBHQ was 2,067 Ϯ 357.5 pA (n ϭ 6). Maximal current amplitude of TRPM2 induced by ADPR after cell rupture was 8,333 Ϯ 666.7 pA (n ϭ 6). Although the current amplitude of TRPM2 induced by TBHQ was only Ϸ25% of the maximal current elicited by Ca 2ϩ /ADPR, these results indicate that [Ca 2ϩ ] i release is capable of activating TRPM2.
Receptor Activation-Induced Ca 2؉ Release Can Activate TRPM2. Because passive Ca 2ϩ release by TBHQ could activate TRPM2, we investigated whether receptor-mediated Ca 2ϩ release was capable of activating TRPM2. As shown in Fig. 6 , under the perforatedpatch configuration, application of 500 M carbachol (CCh) induced typical TRPM2 activation with a linear I-V relation (Fig. 6  A and B) in a pancreatic beta cell (HIT T15 cell). CCh-mediated activation of TRPM2 was through PLC-induced Ca 2ϩ release via IP 3 R because CCh-induced TRPM2 was eliminated by PLC and IP 3 R blockers (Fig. S4 C and D) and largely inhibited by EGTA-AM (Fig. S4A) . The current was readily blocked by 20 M ACA in a reversible manner (Fig. 6 A and B) . Currents elicited by voltage steps also displayed the typical instantaneous activation characteristics of TRPM2 (Fig. 6C) . Current amplitude was larger when 100 M Ca 2ϩ or 200 M ADPR/100 nM Ca 2ϩ was included in the pipette solution for whole-cell current recording (Fig. 6D) . All of the features, including the linear I-V relation, instantaneous activation, and blockade by ACA, are typical characteristics of TRPM2. To further confirm that there was no contamination from Ca 2ϩ -activated TRPM4, which has been shown to express in beta cell lines, including INS-1 and RINm5F (30), we transfected nonfunctional IQ-mut, which can inhibit heterologously expressed TRPM2 but not TRPM4 currents (Fig. 6E) , into HIT T15 cells. Expression of IQ-mut dramatically diminished the current induced by CCh in HIT T15 cells, indicating that the CCh-elicited current in HIT T15 cells is TRPM2 current. Importantly, the TRPM2 current elicited by CCh in HIT T15 cells was not affected by the dominant-negative TRPM4 (DN-TRPM4) transfected into HIT T15 cells (Fig. 6F) . Furthermore, because TRPM2 is Ca 2ϩ - permeable channel, whereas TRPM4 is Ca 2ϩ -impermeable channel, we tested current amplitude by perfusing the cells with isotonic Ca 2ϩ solution. The ratio of the I Ca /I tyrode inward current amplitude of the CCh-activated channel in HIT T15 cells was similar to that of TRPM2 expressed in HEK-293 cells, whereas TRPM4 inward current was virtually eliminated by isotonic Ca 2ϩ solution (Fig. S5) . These results further support that CCh-activated channel in HIT T15 cells is TRPM2. Taken together, our results indicate that Ca 2ϩ release through receptor activation can induce TRPM2 channel activation. This finding implies that TRPM2 may play important roles in response to [Ca 2ϩ ] i release under a variety of physiological conditions.
Discussion
Our results reveal that [Ca 2ϩ ] i plays a pivotal role in TRPM2 channel gating (Fig. S6) : not only is [Ca 2ϩ ] i sufficient to activate TRPM2, but it is required for ADPR-mediated TRPM2 activation. Further, [Ca 2ϩ ] i is capable of activating alternative spliced isoforms of TRPM2, which are insensitive to the full-length TRPM2 agonists, including ADPR. The mechanism of [Ca 2ϩ ] i -mediated TRPM2 activation is via a CaM-binding domain, an IQ-like motif located in the N terminus of TRPM2. Importantly, we found Ca 2ϩ release via receptor activation can activate TRPM2 in intact cells. Our results not only establish that [Ca 2ϩ ] i is an activator of TRPM2 and its spliced isoforms, but also provide new insights into their physiological and/or pathological functions.
[Ca 2؉ ]i Is an Activator for TRPM2 and Its Alternative Spliced Forms. We provide several lines of evidence demonstrating that [Ca 2ϩ ] i is an activator of TRPM2. Both whole-cell and single-channel currents can be activated by [Ca 2ϩ ] i in the absence of ADPR (Figs. 1 and 2) . Moreover, [Ca 2ϩ ] i can activate TRPM2 mutants (N1326D and I1405E/L1406F) that are insensitive to ADPR, NAD ϩ , and H 2 O 2 (13, 19) . More strikingly, [Ca 2ϩ ] i can activate the alternative spliced isoforms, TRPM2-⌬C, TRPM2-⌬N, and TRPM2-⌬C-⌬N, identified in human neutrophil cells (13, 15) , which are insensitive to ADPR and H 2 O 2 (18, 19) (Fig. 4) . These results suggest that [Ca 2ϩ ] i may serve as a major activator in vivo for TRPM2 and its spliced isoforms.
The EC 50 of Ca 2ϩ for WT TRPM2 and N1326D is about 16 M in the presence of 1 mM EGTA. However, this value may have been overestimated, because we found that EGTA can directly block TRPM2 (Fig. S7) . Thus, the EC 50 of Ca 2ϩ should be lower than 16 M in the absence of Ca 2ϩ chelators. Indeed, in the perforatedpatch experiments, TRPM2 can be activated by intracellular Ca 2ϩ release (Figs. 5 and 6 ). Furthermore, because local Ca 2ϩ concentrations can readily reach 100 M in nanodomains and 1-5 M in microdomains (31, 32) , it is likely that TRPM2 or its spliced isoforms can be readily activated by elevation of local [Ca 2ϩ ] i in the absence of ADPR, thereby conferring physiological functions. (29) . Replacement of the motif with AADIVAAAQLA (IQ-mut) disrupted the interaction of CaM and TRPM2 (Fig. S8) , therefore abolishing TRPM2 activation evoked by [Ca 2ϩ ] i and ADPR/Ca 2ϩ (Fig. 4) . These results not only establish that [Ca 2ϩ ] i is necessary and sufficient for TRPM2 activation, but they also elucidate that the Ca 2ϩ -CaM binding to TRPM2 is required for both [Ca 2ϩ ] i -and ADPR/Ca 2ϩ -mediated TRPM2 activation.
The Ca 2ϩ -CaM binding to TRPM2 may also have contributed to the activation kinetics of TRPM2. Previous study has observed that activation time course of TRPM2 is dependent on the concentrations of intracellular activators (17) . We demonstrate that the time course of [Ca 2ϩ ] i gating of TRPM2 is also strongly associated with [Ca 2ϩ ] i concentrations (Fig. S1) [Ca 2ϩ ] i , the differential activation mechanisms and specific distribution pattern of these isoforms (13, 25) suggest that TRPM2 and its spliced isoforms may play distinctive roles.
TRPM2 has been shown to be involved in oxidative stressinduced cell death (5, 8, 10, 34) , mainly because of excessive Ca 2ϩ entry via TRPM2 channels. We have demonstrated that [Ca 2ϩ ] iactivated TRPM2 is about 20-40% of the maximal TRPM2 current amplitude elicited by ADPR/Ca 2ϩ . Thus, TRPM2 may have 2 modes in terms of the execution of physiological functions (Fig. S6 ): In the presence of elevated ADPR concentrations or under oxidative stress conditions, which stimulate ADPR production (35), TRPM2 can be activated to the maximal degree, which may produce detrimental effects and lead to cell death, whereas under normal conditions, when intracellular ADPR is less than 5 M (21) or 1 M (23), increases in [Ca 2ϩ ] i levels locally or globally will elicit moderate TRPM2 activation, thereby conferring physiological functions. Nonetheless, our results provide a novel Ca 2ϩ gating mechanism that may confer novel, yet uncharacterized, physiological functions of TRPM2 and its alternative spliced isoforms.
Conclusions. In the present study, we have demonstrated that [Ca 2ϩ ] i can activate TRPM2 and its alternative spliced isoforms, and that the CaM-binding motif confers [Ca 2ϩ ] i -as well as ADPR/Ca 2ϩ -mediated TRPM2 activation. Importantly, Ca 2ϩ release from intracellular Ca 2ϩ stores can activate TRPM2 in intact cells. Our findings reveal a novel gating mechanism of TRPM2 and its alternative spliced isoforms that may represent a major gating mechanism in vivo, and therefore confer novel, as-yet unknown physiological and/or pathological functions.
Experimental Procedures
Molecular Biology. FLAG-tagged TRPM2 construct was kindly provided by A. Scharenberg (University of Washington, Seattle). Mutations of TRPM2 were made by using the QuikChange Site-Directed Mutagenesis Kit (Stratagene) following the manufacturer's instruction. Truncation mutations were generated by introducing EcoRI sites at the C terminus of TRPM2 for TRPM2-⌬C and by using a primer-loop to delete the 20 residues at the N terminus for generating TRPM2-⌬N. The primers will be available upon request.
Electrophysiology. Whole-cell and single-channel currents were recorded from HEK-293 cells transfected with full-length TRPM2, TRPM2 mutants, and alternative spliced isoforms (SI Materials and Methods). Detailed methods for whole-cell recordings, perforated-patch experiments, and single-channel recordings are described in SI Materials and Methods.
Ratio Ca 2؉ Imaging Experiments. Changes in intracellular Ca 2ϩ were measured by ratio Ca 2ϩ imaging (IonOptix). Simultaneous measurement of Ca 2ϩ signal and TRPM2 activation was conducted by using perforated-patch and ratio imaging on the same cell (SI Materials and Methods).
Immunostaining and Western Blot Experiments. TRPM2-transfected cells were immunostained with ␣-FLAG antibody. The immunostained cells were analyzed by using a Zeiss LSM 510 confocal microscope. Protein expression was detected by Western blot experiments with anti-FLAG antibody. Surface and cytosol proteins were extracted by using the biotinylation method (SI Materials and Methods).
Data Analysis. Pooled data are presented as mean Ϯ SEM. Dose-response curves were fitted by an equation: E ϭ Emax{1/[1ϩ(EC50/C) n ]}, where E is the effect at concentration C, Emax is maximal effect, EC50 is the concentration for half-maximal effect, and n is the Hill coefficient. EC50 is replaced with IC50 if the effect is an inhibitory effect. Statistical comparisons were made by using 2-way ANOVA and 2-tailed t test with Bonferroni correction. P Ͻ 0.05 indicated statistical significance.
